Table 2.
TRIAL | Phase | Patients | Inclusion Criteria | Experimental Treatment |
---|---|---|---|---|
Pich (NCT03114280) | I/II | 55 | Stage III–V oral cavity, oropharynx and hypopharynx) | 3 cycles of TPF + Pembrolizumab |
NCT03342911 | II | 37 | Stage III–IV oral cavity, oropharynx and hypopharynx) | 3 cycles of carboplatin + paclitaxel + Nivolumab |
Medinduction (NCT02997332) | I | 36 | Stage III–IV oral cavity, oropharynx and hypopharynx) | 3 cycles of TPF + Durvalumab |